NASDAQ:ZYXI Zynex (ZYXI) Stock Price, News & Analysis → This Apple-like Innovator is Revolutionizing Healthcare (From Wall Street Star) (Ad) Free ZYXI Stock Alerts $11.35 +0.09 (+0.80%) (As of 11:29 AM ET) Add Compare Share Share Today's Range$11.33▼$11.5350-Day Range$11.14▼$13.7452-Week Range$6.88▼$14.75Volume41,012 shsAverage Volume237,059 shsMarket Capitalization$365.13 millionP/E Ratio42.04Dividend YieldN/APrice Target$18.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get Zynex alerts: Email Address Zynex MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside59.9% Upside$18.00 Price TargetShort InterestBearish31.73% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.00Based on 2 Articles This WeekInsider TradingN/AProj. Earnings Growth91.84%From $0.49 to $0.94 Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.74 out of 5 starsMedical Sector414th out of 909 stocksElectromedical Equipment Industry7th out of 18 stocks 3.5 Analyst's Opinion Consensus RatingZynex has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageZynex has only been the subject of 2 research reports in the past 90 days. Previous Next 1.0 Short Interest Percentage of Shares Shorted31.73% of the float of Zynex has been sold short.Short Interest Ratio / Days to CoverZynex has a short interest ratio ("days to cover") of 22.9, which indicates bearish sentiment.Change versus previous monthShort interest in Zynex has recently decreased by 1.37%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldZynex does not currently pay a dividend.Dividend GrowthZynex does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ZYXI. Previous Next 0.6 News and Social Media Coverage News Coverage This WeekMarketBeat has tracked 2 news articles for Zynex this week, compared to 1 article on an average week.Search Interest6 people have searched for ZYXI on MarketBeat in the last 30 days. This is an increase of 20% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Zynex insiders have not sold or bought any company stock.Percentage Held by Insiders52.13% of the stock of Zynex is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 29.68% of the stock of Zynex is held by institutions. Previous Next 3.1 Earnings and Valuation Earnings GrowthEarnings for Zynex are expected to grow by 91.84% in the coming year, from $0.49 to $0.94 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Zynex is 41.70, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 135.07.Price to Earnings Ratio vs. SectorThe P/E ratio of Zynex is 41.70, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 167.00.Price to Book Value per Share RatioZynex has a P/B Ratio of 8.28. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Paradigm PressBiden replacement revealed?A former CIA insider just announced a disturbing prediction… Biden will withdraw as the Democrat nominee on June 13.See his shocking evidence in this new report About Zynex Stock (NASDAQ:ZYXI)Zynex, Inc., together with its subsidiaries, designs, manufactures, and markets medical devices to treat chronic and acute pain; and activate and exercise muscles for rehabilitative purposes with electrical stimulation. The company offers NexWave, a dual channel, multi-modality interferential current, transcutaneous electrical nerve stimulation, and neuromuscular electrical stimulation (NMES) device that is marketed to physicians and therapists by field sales representatives; NeuroMove, an electromyography and electric stimulation technology device; InWave, an electrical stimulation product for the treatment of female urinary incontinence; E-Wave, an NMES device; M-Wave, an NMES device. It also supplies private labeled products, including electrodes for the delivery of electrical current to the body, and batteries for use in electrotherapy products. In addition, the company distributes Comfortrac/Saunders for cervical traction, JetStream for hot/cold therapy, LSO Back Braces for lumbar support, and braces for rehabilitation support. Further, it offers Zynex Fluid Monitoring System (CM-1500); Zynex Wireless Fluid Monitoring System (CM-1600), a noninvasive monitoring device designed to measure relative changes in fluid volume in adult patients; NiCO CO-Oximeter, a laser-based noninvasive co-oximeter; and HemeOx tHb Oximeter, a laser-based total hemoglobin pulse oximeter. The company provides its products for use in pain management and control; stroke and spinal cord injury rehabilitation; hemodynamic monitoring and intravascular volume monitoring; and pulse oximetry monitoring. It sells its products through direct sales force primarily in the United States. Zynex, Inc. was founded in 1996 and is headquartered in Englewood, Colorado.Read More ZYXI Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ZYXI Stock News HeadlinesApril 21, 2024 | americanbankingnews.comCritical Comparison: Galenica (OTCMKTS:GALNF) & Zynex (NASDAQ:ZYXI)April 18, 2024 | prnewswire.comZynex Sets First Quarter 2024 Earnings CallApril 24, 2024 | Insiders Exposed (Ad)The Hard Truth About Investing For RetirementHere’s the cold, hard truth about investing: The more capital you have, the more risk averse you can afford to be. But when you’re staring down the barrel of retirement and you’ve only got 5, 10, 50 or $100,000 saved, you’ve got to be more aggressive. In an exclusive online training, the Market expert Steven Place is revealing a powerful “roadmap” that’s leading everyday investors to easy, triple-digit wins, even if they don’t have a lot of experience in trading.April 2, 2024 | investorplace.com3 Industrial Stocks Short Sellers Are Hammering: Cracks in the Foundation?April 2, 2024 | prnewswire.comZynex Earns Prestigious 2024 Top Workplaces USA Employer Recognition AwardMarch 30, 2024 | finance.yahoo.comWith 51% ownership, Zynex, Inc. (NASDAQ:ZYXI) insiders have a lot riding on the company's futureMarch 16, 2024 | finance.yahoo.comZYXI Aug 2024 20.000 callMarch 15, 2024 | wsj.comZynex Inc.April 24, 2024 | Insiders Exposed (Ad)The Hard Truth About Investing For RetirementHere’s the cold, hard truth about investing: The more capital you have, the more risk averse you can afford to be. But when you’re staring down the barrel of retirement and you’ve only got 5, 10, 50 or $100,000 saved, you’ve got to be more aggressive. In an exclusive online training, the Market expert Steven Place is revealing a powerful “roadmap” that’s leading everyday investors to easy, triple-digit wins, even if they don’t have a lot of experience in trading.March 3, 2024 | finance.yahoo.comZynex Full Year 2023 Earnings: Misses ExpectationsMarch 2, 2024 | seekingalpha.comZynex, Inc. (ZYXI) Q4 2023 Earnings Call TranscriptMarch 2, 2024 | finance.yahoo.comZynex, Inc. (NASDAQ:ZYXI) Q4 2023 Earnings Call TranscriptMarch 1, 2024 | markets.businessinsider.comHere's what to expect from Zynex's earningsMarch 1, 2024 | finance.yahoo.comZynex Price Target Raised by RBC Capital, HC Wainwright AnalystsFebruary 29, 2024 | benzinga.comZynex: Q4 Earnings InsightsFebruary 29, 2024 | msn.comZynex GAAP EPS of $0.04 misses by $0.13, revenue of $47.28M misses by $8.34MFebruary 29, 2024 | finance.yahoo.comZynex Inc (ZYXI) Reports 17% Revenue Growth in FY 2023, Announces New $20 Million Stock ...February 29, 2024 | finance.yahoo.comZynex Reports Fourth Quarter and Full Year 2023 Financial ResultsFebruary 29, 2024 | prnewswire.comZynex Reports Fourth Quarter and Full Year 2023 Financial ResultsFebruary 28, 2024 | benzinga.comEarnings Preview: ZynexFebruary 22, 2024 | finance.yahoo.comZynex Sets Fourth Quarter and Full Year 2023 Earnings CallFebruary 22, 2024 | prnewswire.comZynex Sets Fourth Quarter and Full Year 2023 Earnings CallFebruary 20, 2024 | finance.yahoo.comZynex Introduces New ProductsFebruary 20, 2024 | prnewswire.comZynex Introduces New ProductsFebruary 6, 2024 | msn.comZynex gets FDA clearance for M-Wave muscle stimulation deviceFebruary 6, 2024 | markets.businessinsider.comZynex Says FDA Clears M-Wave Neuromuscular Electrical Stimulation DeviceFebruary 6, 2024 | finance.yahoo.comZynex Receives FDA Clearance for its Next Generation NMES DeviceSee More Headlines Receive ZYXI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Zynex and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/29/2024Today4/24/2024Next Earnings (Estimated)4/25/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Electromedical equipment Sub-IndustryN/A Current SymbolNASDAQ:ZYXI CUSIPN/A CIK846475 Webwww.zynex.com Phone(303) 703-4906FaxN/AEmployees1,100Year FoundedN/APrice Target and Rating Average Stock Price Target$18.00 High Stock Price Target$21.00 Low Stock Price Target$15.00 Potential Upside/Downside+58.6%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)$0.27 Trailing P/E Ratio42.04 Forward P/E Ratio23.16 P/E GrowthN/ANet Income$9.73 million Net Margins5.28% Pretax Margin6.82% Return on Equity16.82% Return on Assets7.05% Debt Debt-to-Equity Ratio1.26 Current Ratio4.74 Quick Ratio4.03 Sales & Book Value Annual Sales$184.32 million Price / Sales1.98 Cash Flow$0.42 per share Price / Cash Flow27.07 Book Value$1.36 per share Price / Book8.35Miscellaneous Outstanding Shares32,170,000Free Float15,400,000Market Cap$365.13 million OptionableOptionable Beta0.48 These 7 Stocks Will Be Magnificent in 2024With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.Get This Free Report Key ExecutivesMr. Thomas Sandgaard (Age 65)Founder, President, CEO & Chairman Comp: $992.83kMr. Daniel J. Moorhead (Age 52)Chief Financial Officer Comp: $472.61kMs. Anna Lucsok (Age 37)Chief Operating Officer Comp: $400.84kMr. Steve FoxVice President Of SalesMr. Donald GreggPresident of Zynex Monitoring SolutionsMr. Neil FrieryPresident & COO of Zynex Monitoring Solutions, Inc.More ExecutivesKey CompetitorsAxoGenNASDAQ:AXGNEdap TmsNASDAQ:EDAPSemler ScientificNASDAQ:SMLRElectromedNYSE:ELMDOutset MedicalNASDAQ:OMView All CompetitorsInsiders & InstitutionsRice Hall James & Associates LLCBought 122,128 shares on 4/23/2024Ownership: 0.754%Platte River Wealth Advisors LLCSold 5,000 shares on 4/23/2024Ownership: 0.031%Allspring Global Investments Holdings LLCSold 7,990 shares on 4/18/2024Ownership: 0.027%Bridge City Capital LLCBought 7,270 shares on 4/12/2024Ownership: 0.580%Congress Asset Management Co. MABought 1,225 shares on 4/11/2024Ownership: 0.368%View All Insider TransactionsView All Institutional Transactions ZYXI Stock Analysis - Frequently Asked Questions Should I buy or sell Zynex stock right now? 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Zynex in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" ZYXI shares. View ZYXI analyst ratings or view top-rated stocks. What is Zynex's stock price target for 2024? 2 Wall Street research analysts have issued 1 year target prices for Zynex's stock. Their ZYXI share price targets range from $15.00 to $21.00. On average, they anticipate the company's stock price to reach $18.00 in the next year. This suggests a possible upside of 59.9% from the stock's current price. View analysts price targets for ZYXI or view top-rated stocks among Wall Street analysts. How have ZYXI shares performed in 2024? Zynex's stock was trading at $10.89 at the beginning of 2024. Since then, ZYXI stock has increased by 3.4% and is now trading at $11.26. View the best growth stocks for 2024 here. When is Zynex's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, April 25th 2024. View our ZYXI earnings forecast. How were Zynex's earnings last quarter? Zynex, Inc. (NASDAQ:ZYXI) issued its earnings results on Thursday, February, 29th. The company reported $0.04 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.17 by $0.13. The firm had revenue of $47.28 million for the quarter, compared to the consensus estimate of $54.53 million. Zynex had a net margin of 5.28% and a trailing twelve-month return on equity of 16.82%. The business's revenue was down 3.1% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.20 earnings per share. What guidance has Zynex issued on next quarter's earnings? Zynex updated its first quarter 2024 earnings guidance on Thursday, February, 29th. The company provided earnings per share guidance of 0.030- for the period, compared to the consensus EPS estimate of 0.040. The company issued revenue guidance of $47.5 million-, compared to the consensus revenue estimate of $47.7 million. What is Thomas Sandgaard's approval rating as Zynex's CEO? 81 employees have rated Zynex Chief Executive Officer Thomas Sandgaard on Glassdoor.com. Thomas Sandgaard has an approval rating of 87% among the company's employees. Who are Zynex's major shareholders? Zynex's stock is owned by many different institutional and retail investors. Top institutional investors include Rice Hall James & Associates LLC (0.75%), Bridge City Capital LLC (0.58%), Congress Asset Management Co. MA (0.37%), Platte River Wealth Advisors LLC (0.03%) and Allspring Global Investments Holdings LLC (0.03%). Insiders that own company stock include Anna Lucsok, Daniel J Moorhead and Thomas Sandgaard. View institutional ownership trends. How do I buy shares of Zynex? Shares of ZYXI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:ZYXI) was last updated on 4/24/2024 by MarketBeat.com Staff From Our PartnersThis Apple-like Innovator is Revolutionizing HealthcareWall Street Startop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsBitcoin Rockets To Record High But Buy THIS InsteadParadigm PressThe #1 Crypto for 2024InvestorPlaceDon’t Miss Out on the AI Gold Rush That’s Just Getting StartedBanyan Hill PublishingPrepare for a recession unlike any otherAmerican Hartford Gold GroupExposed: How Big Banks Plan to Chain Your Wealth with Digital DollarsGoldenCrest Metals Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Zynex, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
